Tag Archives: Verastem

Verastem director Brian Stuglik sells shares worth $937,000, sparking curiosity among investors and industry watchers. The move comes amidst a backdrop of recent developments at Verastem, a company focused on developing innovative cancer therapies. Stuglik, a seasoned executive with a deep understanding of the pharmaceutical landscape, has been a key …

Verastem CEO sells shares worth $513 to cover tax obligations, a move that has sparked curiosity and speculation within the financial community. This strategic decision by the CEO, a key figure in the biotechnology industry, has raised questions about Verastem’s financial standing and future prospects. Verastem, a company focused on …

Verastem director sells shares worth 5 to meet tax obligations – Verastem director sells shares worth $365 million to meet tax obligations, a move that has sent ripples through the pharmaceutical industry. This transaction, involving a significant number of shares, has sparked speculation about the company’s future prospects and the …